Highlights Clene Inc.

Equities

CLNN

US1856341029

Delayed Nasdaq Other stock markets 19:48:39 15/05/2024 BST			5-day change	1st Jan Change
0.38 ^USD	-1.07%		-2.54%	+28.12%

05-08	Earnings Flash (CLNN) CLENE Reports Q1 Revenue $73M	MT
04-16	Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (CLNN) CLENE Reports Q1 Revenue $73M	05-08	MT
Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	04-16	CI
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	03-15	CI
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
North American Morning Briefing : Stock Futures -2-	03-11	DJ
Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs	02-22	CI
Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial	01-08	CI
US FDA finds Clene's trial data for ALS drug to be insufficient	12-21	RE
Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases	12-14	CI
Earnings Flash (CLNN) CLENE Reports Q3 Revenue $108M	11-07	MT
Clene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Clene Shares Jump After Being Awarded $45.1 Million Government Grant for Investigational ALS Drug	05/10/23	MT
Clene Awarded $45.1 Million Government Grant to Fund EAP for Investigational ALS Drug	05/10/23	MT
Earnings Flash (CLNN) CLENE Posts Q2 Revenue $269,000	14/08/23	MT
Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Clene Announces Publication of Phase 2 CNM-Au8Â® Clinical Data for the Treatment of ALS in LANCETâ€™s eClinicalMedicine	26/06/23	CI
Clene’S Cnm-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light Levels in the Healey Als Platform Trial	15/06/23	CI
North American Morning Briefing : Hopes Build for -3-	15/05/23	DJ
Clene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Earnings Flash (CLNN) CLENE Posts Q1 Revenue $107,000	12/05/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Clene Inc.

Equities

CLNN

US1856341029

Highlights

Filters